Latest Nucleosides Stories
The Need for More-Efficacious Treatments Creates Significant Opportunity for Drug Developers in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., May 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2012, growth in the myelodysplastic syndromes drug market will be driven principally by the launch in Europe of Celgene's Vidaza and Revlimid.
VIDAZA Restores Gene Function to Double Survival and Increase Transfusion Independence CROSSWICKS, N.J., Feb.
- Conference Call at 10:00 A.M. Today to Discuss Results - EXTON, Pa., Feb.
Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents WOODCLIFF LAKE, N.J., Dec.
The Aplastic Anemia & MDS International has announced that the European Committee for Medicinal Products for Human Use has awarded Vidaza a positive opinion for the treatment of myelodysplastic syndromes patients who are not eligible for stem cell transplants.
Celgene International has announced that its cancer drug, Vidaza, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of adult patients with myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced that it has advanced sapacitabine into Phase 2 development as a second-line treatment for myelodysplastic syndromes (MDS).
The Moffitt Cancer Center announced today that Dr. Alan List, Physician-in-Chief, was one of the key investigators in a VIDAZA (azacitidine) clinical trial (AZA-001) whose results the U.S. Food & Drug Administration (FDA) has approved to add to the drug's label.
The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial.
Celgene has announced that Vidaza has received expanded FDA approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes.
- A political dynamiter.